Pain ManagementNeurologyPsychiatryEndocrinologyOncologyNeuroscienceCentral Nervous SystemHepatologyBiotechnologyPharmaceuticalProduct Research
Description
Ipsen S.A. operates as a global biopharmaceutical group dedicated to the development of innovative medicines that meet the critical medical needs of patients around the world.
The company is known for its focus on specialty care, particularly in are…
Analysis
Quality compounder
Ipsen S.A. is a quality compounder: a well-run business trading at a price that reflects what it is worth.
The price is fair. You pay 19.5× its owner earnings: the cash an owner could take out each year, which is in the historically fair zone. At today's price, the market is assuming roughly 6% yearly growth; analysts expect 7%. The price, in other words, assumes less than the experts do.
The trajectory is moderate and the balance sheet is sturdy. The company scores 18/20 on our value-creation score: strong value creator. Analyst sentiment is cautious.
Nothing is flagged here: no red or amber gates, no divergence between profits and cash. That is itself information: the numbers are straightforward. As always: this describes the company's numbers; it is not a recommendation.
360° rank · history
1007550250
Jan 202398
86
2023202420252026
All-time high
98
Mar 2026
All-time low
45
Jan 2024
Average rank
83
across all years
Detailed & Historical Ranks
Deep dive into 15 detailed ranks and 3 years of history.
Current202520242023
Price/Sales
68
53
52
79
Price/Earnings
64
89
81
92
Price/Book
69
67
57
69
Dividend Yield
55
45
49
51
Value (overall)
85
80
67
69
Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.